Development of a bioassay for anti tumor activity of biological response modifiers of the reticuloendothelial stimulant class: reproducibility of the bioassay.
Intravenously administered DiLuzio glucan, Wellcome C. parvum, and Glaxo BCG caused dose dependent increases in the tumor cell loss from the lungs of C57BL/6J and DBA/2J mice challenged respectively with intravenous 125IuDR labelled B16 or T 1699 mammary carcinoma cells. The results were reproducible with respect to the optimal doses and the magnitudes and shapes of the dose response curves.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001688:Biological Products / Q000494:pharmacology; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D005936:Glucans / Q000494:pharmacology; D007158:Immunologic Techniques; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000276:immunology; D008545:Melanoma / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D012157:Mononuclear Phagocyte System / Q000276:immunology*; D009163:Mycobacterium bovis / Q000276:immunology; D009374:Neoplasms, Experimental / Q000276:immunology*; D011425:Propionibacterium acnes / Q000276:immunology
D000276:Adjuvants, Immunologic; D001688:Biological Products; D005936:Glucans